[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-219736-105":53,"doc-detail-219736-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","the-use-of-cryopreserved-ovarian-tissue-to-restore-ovarian-function-chairs-foreword","The Use of Cryopreserved Ovarian Tissue to Restore Ovarian Function - Chair’s foreword","","A consultation document from the Advisory Committee on Assisted Reproductive Technology presents proposed advice to the Minister of Health to establish the use of cryopreserved ovarian tissue to restore ovarian function as an established procedure. The proposed approach would allow stored ovarian tissue to be used by fertility clinics for women to access their own reproductive function without Ethics Committee approval. The foreword explains the evolving assisted reproduction landscape under the HART Act, reviews evidence, and considers risks, benefits, and ethical issues.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/the-use-of-cryopreserved-ovarian-tissue-to-restore-ovarian-function-chairs-foreword/219736/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/the-use-of-cryopreserved-ovarian-tissue-to-restore-ovarian-function-chairs-foreword/219736.png","ImageObject",442,249,{"name":88,"@type":89},"Lute","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-10-23","2026-09-08",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",10,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What change does ACART propose regarding cryopreserved ovarian tissue?","Question",{"text":109,"@type":110},"ACART proposes that using cryopreserved ovarian tissue to restore ovarian function becomes an established procedure.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What would “established procedure” enable for patients and clinics?",{"text":114,"@type":110},"Stored ovarian tissue could be used by fertility clinics to restore a woman’s own reproductive function without needing ethics approval by ECART.",{"name":116,"@type":107,"acceptedAnswer":117},"How does the document address regulation and ethical considerations?",{"text":118,"@type":110},"It frames the proposal within New Zealand’s HART Act and reports that ACART reviewed evidence while considering risks, benefits, and ethical issues.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},219736,1788888638,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":12,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":126,"read_time":140},137454149569,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Advisory Committee on\u000bAssisted Reproductive Technology\nThe Use of Cryopreserved Ovarian Tissue to Restore Ovarian Function\nProposed advice\u000bto the Minister of Health\nConsultation Document\nCitation: Advisory Committee on Assisted Reproductive Technology. 2016. The Use of Cryopreserved Ovarian Tissue to Restore Ovarian Function: Proposed advice to the Minister of Health. Wellington: Advisory Committee on Assisted Reproductive Technology.\nPublished in April 2016 by the Advisory Committee on Assisted Reproductive Technology, PO Box 5013, Wellington 6145, New Zealand\nISBN 978-0-947491-90-1 (online)\u000bHP 6386\nThis document is available on the ACART website:\u000bwww.acart.health.govt.nz\nChair’s foreword\nThe Advisory Committee on Assisted Reproductive Technology (ACART) has prepared this consultation document to present proposed advice to the Minister of Health that the use of cryopreserved ovarian tissue to restore ovarian function become an established procedure. This means that stored ovarian tissue could be used by fertility clinics to restore a woman’s own reproductive function without the need for ethical approval by the Ethics Committee on Assisted Reproductive Technology (ECART).\nHuman assisted reproductive technologies are continuously developing and rapidly changing. This dynamic is recognised in New Zealand’s Human Assisted Reproductive Technology Act 2004 (HART Act). The HART Act seeks to secure the benefits of assisted reproductive technology while protecting the health and safety of all individuals, particularly women and children, in the use of these technologies.\nACART has previously provided advice to the Minister that a procedure or treatment become an established procedure. In 2009, following ACART’s advice to the Minister, the use of frozen eggs in fertility treatment became an established procedure.\nOvarian tissue cryopreservation was declared an established procedure in 2005. The subsequent use of the tissue was not, as the safety of its use could not be adequately assessed at the time. ACART is now proposing to advise the Minister that the use of cryopreserved ovarian tissue to restore ovarian function become an established procedure. Currently women in New Zealand are able to cryopreserve and store ovarian tissue, but are unable to use it. ACART has reviewed the recent evidence and considered the risks, benefits and ethical issues associated with the use of cryopreserved ovarian tissue. ACART has concluded that there is good to reason to allow women to use cryopreserved ovarian tissue to restore ovarian function as an established procedure.\nWe welcome feedback on our proposed advice to the Minister. Your comments will help ACART to finalise its advice to the Minister on the use of cryopreserved ovarian tissue to restore ovarian function.\nAlison Douglass\nChair, Advisory Committee on Assisted Reproductive Technology\nApril 2016\nHow to have your say\nYour feedback is important to help ACART finalise its advice to the Minister of Health on the use of cryopreserved ovarian tissue to restore ovarian function.\nPlease take this opportunity to have your say. A feedback form is at the back of this document. You may give feedback on your own behalf or as a member of an organisation. You can contribute your views by:\n1.\temailing a completed feedback form or your comments to \u0013 HYPERLINK \"mailto:acart@moh.govt\" \u0014acart@moh.govt\u0015, or\n2.\tposting a completed feedback form or your comments to:\nACART Secretariat\nPO Box 5013\nWellington.\nACART welcomes your views on any or all of the issues raised.\nPublication of feedback on ACART’s website\nWe will place all feedback on ACART’s website as it is received, including your name and contact details, unless you request otherwise by ticking the relevant boxes in the feedback form.\nOfficial Information Act requests — feedback\nPlease note that all feedback, including your name and contact details, may be requested by any member of the public under the Official Information Act 1982 (the Act). The Act ","cbCaiv9RAUCMTvJV","https://ap.wps.com/l/cbCaiv9RAUCMTvJV","docx",945708,"English","# Chair’s foreword\n# How to have your say\n# Executive summary\n# 1 Introduction\n## Purpose\n## Scope of ACART’s proposed advice\n## ACART’s role\n# 2 Background: ovarian tissue cryopreservation\n## What is ovarian tissue cryopreservation?\n## Ovarian tissue cryopreservation in New Zealand","[{\"question\":\"What change does ACART propose regarding cryopreserved ovarian tissue?\",\"answer\":\"ACART proposes that using cryopreserved ovarian tissue to restore ovarian function becomes an established procedure.\"},{\"question\":\"What would “established procedure” enable for patients and clinics?\",\"answer\":\"Stored ovarian tissue could be used by fertility clinics to restore a woman’s own reproductive function without needing ethics approval by ECART.\"},{\"question\":\"How does the document address regulation and ethical considerations?\",\"answer\":\"It frames the proposal within New Zealand’s HART Act and reports that ACART reviewed evidence while considering risks, benefits, and ethical issues.\"}]","The Use of Cryopreserved Ovarian Tissue to Restore Ovarian Function - Chair’s foreword | DOCX",31]